User menu

[18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model

Bibliographic reference Dubois, Ludwig ; Landuyt, Willy ; Cloetens, Lieselotte ; Bol, Anne ; Bormans, Guy M. ; et. al. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 36, no. 2, p. 209-218 (2009)
Permanent URL http://hdl.handle.net/2078.1/25013
  1. Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer 1984;54:2441–9.
  2. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449–65.
  3. Brizel David M., Sibley Gregory S., Prosnitz Leonard R., Scher Richard L., Dewhirst Mark W., Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck, 10.1016/s0360-3016(97)00101-6
  4. Wouters BG, Koritzinsky M, Chiu RK, Theys J, Buijsen J, Lambin P. Modulation of cell death in the tumor microenvironment. Semin Radiat Oncol 2003;13:31–41.
  5. Magagnin MG, Koritzinsky M, Wouters BG. Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies. Drug Resist Updat 2006;9:185–97.
  6. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265–80.
  7. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321–9.
  8. Koh Wui-Jin, Rasey Janet S., Evans Margaret L., Grierson John R., Lewellen Thomas K., Graham Michael M., Krohn Kenneth A., Griffin Thomas W., Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole, 10.1016/0360-3016(92)91001-4
  9. Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999;40:1072–9.
  10. Zanzonico P, O’Donoghue J, Chapman JD, Schneider R, Cai S, Larson S, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117–28.
  11. Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987;111:292–304.
  12. Bentzen L, Keiding S, Horsman MR, Gronroos T, Hansen SB, Overgaard J. Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol 2002;41:304–12.
  13. Dubois L, Landuyt W, Haustermans K, Dupont P, Bormans G, Vermaelen P, et al. Evaluation of hypoxia in an experimental rat tumour model by [18F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004;91:1947–54.
  14. Tochon-Danguy HJ, Sachinidis JI, Chan F, Chan JG, Hall C, Cher L, et al. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F]fluoromisonidazole (FMISO). Nucl Med Biol 2002;29:191–7.
  15. Troost EG, Laverman P, Kaanders JH, Philippens M, Lok J, Oyen WJ, et al. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol 2006;80:157–64.
  16. Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006;6:51.
  17. Rajendran JG, Schwartz DL, O’Sullivan J, Peterson LM, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435–41.
  18. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006;80:151–6.
  19. Zimny M, Gagel B, Dimartino E, Hamacher K, Coenen HH, Westhofen M, et al. FDG-a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO (2)-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006;33:1426–31.
  20. Gronroos T, Bentzen L, Marjamaki P, Murata R, Horsman MR, Keiding S, et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004;31:513–20.
  21. Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59:971–82.
  22. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106–13.
  23. Sorger D, Patt M, Kumar P, Wiebe LI, Barthel H, Seese A, et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003;30:317–26.
  24. Dewhirst MW. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Oncol 1998;8:143–50.
  25. Busch TM, Hahn SM, Evans SM, Koch CJ. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide]. Cancer Res 2000;60:2636–42.
  26. Koch CJ. Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol 2002;352:3–31.
  27. Josse O, Labar D, Georges B, Gregoire V, Marchand-Brynaert J. Synthesis of [18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia. Bioorg Med Chem 2001;9:665–75.
  28. Mahy P., De Bast M., Leveque P.H., Gillart J., Labar D., Marchand J., Gregoire V., Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[18F]trifluoropropyl)acetamide, [18F]EF3, 10.1007/s00259-004-1573-2
  29. Barendsen G.W., Broerse J.J., Experimental radiotherapy of a rat rhabdomyosarcoma with 15 MeV neutrons and 300 kV X-rays, 10.1016/0014-2964(69)90051-6
  30. Lim JL, Berridge MS. An efficient radiosynthesis of [18F]fluoromisonidazole. Appl Radiat Isot 1993;44:1085–91.
  31. Bentzen L, Keiding S, Horsman MR, Falborg L, Hansen SB, Overgaard J. Feasibility of detecting hypoxia in experimental mouse tumours with 18F-fluorinated tracers and positron emission tomography—a study evaluating [18F]Fluoro-2-deoxy-D-glucose. Acta Oncol 2000;39:629–37.
  32. Mahy P, De Bast M, Gillart J, Labar D, Gregoire V. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging 2006;33:553–6.
  33. Lehtio K, Oikonen V, Nyman S, Gronroos T, Roivainen A, Eskola O, et al. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 2003;30:101–8.
  34. Ziemer L., Evans S., Kachur A., Shuman A., Cardi C., Jenkins W., Karp J., Alavi A., Dolbier W., Koch C., Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5, 10.1007/s00259-002-1037-5
  35. Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 2000;41:327–36.
  36. Christian N, Bol A, De Bast M, Labar D, Lee J, Mahy P, et al. Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. Eur J Nucl Med Mol Imaging 2007;34:1348–54.
  37. Rajendran J. G., Wilson D. C., Conrad E. U., Peterson L. M., Bruckner J. D., Rasey J. S., Chin L. K., Hofstrand P. D., Grierson J. R., Eary J. F., Krohn K. A., [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression, 10.1007/s00259-002-1096-7
  38. Skov K, Adomat H, Bowden M, Dragowska W, Gleave M, Koch CJ, et al. Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages. Radiat Res 2004;162:547–53.
  39. Stadler Peter, Becker Axel, Jürgen Feldmann Horst, Hänsgen Gabriele, Dunst Jürgen, Würschmidt Florian, Molls Michael, Influence of the hypoxic subvolume on the survival of patients with head and neck cancer, 10.1016/s0360-3016(99)00115-7
  40. Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 2006;24:146–50.